E Ink Launches E Ink Gallery 3 Color ePaper for Sustainable Digital Reading
Featuring faster page turns and color switching for eReader Market BILLERICA, Mass.–(BUSINESS WIRE)–E Ink (8069.TWO),…
Featuring faster page turns and color switching for eReader Market BILLERICA, Mass.–(BUSINESS WIRE)–E Ink (8069.TWO),…
25th April 2022: Ballymore Group founder and Group CEO Sean Mulryan has acquired a significant…
Expanding Leadership Team to Accelerate Development of Innovative Therapeutic Delivery Platforms SAN DIEGO, April 25,…
Castellum, Inc. Hires David T. Bell as Chief Financial Officer Castellum, Inc. (OTC: ONOV) announces…
– Strategic areas of focus on development of BDTX-1535 and BDTX-4933 as well as MAP…
– Q&A Session at Conference on Wednesday, April 27th at 1:30PM Eastern – AUSTIN, Texas,…
SAN DIEGO and PALO ALTO, Calif., April 25, 2022 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc….
LAVAL, Québec, April 25, 2022 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”)…
MIAMI, April 25, 2022 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a biopharmaceutical company, today…
BOSTON, April 25, 2022 (GLOBE NEWSWIRE) — Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:…
Quoin Will Initiate Clinical Testing in 1H 2022 ASHBURN, Va., April 25, 2022 (GLOBE NEWSWIRE)…
Preclinical data published in Molecular Therapy Nucleic Acids demonstrate that WVE-004 potently reduces C9orf72 transcriptional…
Chief Science Officer and CB Therapeutics co-founder, Dr. Jacob Vogan, working alongside Laboratory Manager, Diana…
The Company to Host a Conference Call and Webcast on May 11, 2022, at 8:30…
– Company advancing development of its Autoimmunity Modifying AIM Biologicals as a potential therapeutic treatment…
– Met pre-specified efficacy endpoints in chronic pouchitis, a difficult-to-treat inflammatory bowel disease (IBD)– AMT-101…
PURCHASE, N.Y., April 25, 2022 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical…
Results from patient preference questionnaire indicate that people with narcolepsy preferred the once-nightly over the…
MONTREAL, April 25, 2022 (GLOBE NEWSWIRE) — Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”), a…
Collaboration will advance preclinical and potential clinical development of STING agonists and anti-RAGE agents for…